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High-grade gliomas are aggressive and uniformly
fatal tumors, composed of a heterogeneous popula-
tion of cells that include many with stem-cell-like
properties. The acquisition of stem-like traits might
contribute to glioma initiation, growth, and recur-
rence. Here we investigated the role of the transcrip-
tion factor myeloid Elf-1 like factor (MEF, also known
as ELF4) in gliomas. We found that MEF is highly ex-
pressed in both human and mouse glioblastomas
and its absence impairs gliomagenesis in a PDGF-
driven glioma mouse model. We show that modula-
tion of MEF levels in both mouse neural stem
cells and human glioblastoma cells has a signifi-
cant impact on neurosphere formation. Moreover,
we identify Sox2 as a direct downstream target of
MEF. Taken together, our studies implicate MEF as
a previously unrecognized gatekeeper gene in glio-
magenesis that promotes stem cell characteristics
through Sox2 activation.
INTRODUCTION
Malignant gliomas represent the most prevalent primary brain
tumor in adults and inevitably have a poor prognosis. Despite
the implementation of new therapeutic strategies, the median
survival of patients with Glioblastoma multiforme (GBM),
the most aggressive glioma variant, is only 14–16 months
and these tumors remain rapidly and uniformly fatal (Wen and
Kesari, 2008).836 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier InGBMs are very heterogeneous tumors that contain both
neoplastic and nonneoplastic cells, including endothelial,
stromal, and inflammatory cells (Charles et al., 2011). A fraction
of cells within the tumor, identified as glioma stem-like cells
(GSCs), share some common features with normal neural stem
cells (NSCs); they are multipotent and have the property of
self-renewal. These cells may either derive from adult undifferen-
tiated stem and progenitor cells or could acquire stem-like
properties as a result of the genetic alterations that promote
the tumorigenic process (Holmberg et al., 2011). When im-
planted into the brain of immunodeficient animals, these GSCs
are capable of generating new tumors at high efficiency (Galli
et al., 2004). Moreover, GSCs are remarkably resistant to the
chemotherapy and radiotherapy (Dean et al., 2005) used as
standard first-line treatment of patients with malignant gliomas.
Indeed, acquisition of stem-like characteristics likely contributes
to the malignant nature of high-grade gliomas and may be
responsible for the initiation, growth, and recurrence of these
tumors.
Myeloid Elf-1 like factor (MEF, also known as ELF4) is a
member of the ETS family of transcription factors, which
contains over 30 family members. Several ETS proteins can
function as oncogenes and show aberrant expression in solid
tumors as well as in hematological malignancies (Sashida
et al., 2010). While MEF has been proposed to function as
a tumor suppressor gene in some contexts, it could contribute
to tumor formation in mice as well as in humans (Mikkers et al.,
2002) (Sashida et al., 2010). Insight into its mechanism of action
has come from studies done in fibroblasts demonstrating MEF’s
ability to induce transformation by stimulatingMdm2 expression,
thereby downregulating p53-dependent responses, and by
inhibiting activation of Ink4a, thereby allowing unrestrained
phosphorylation of the retinoblastoma (Rb) protein (Sashida
et al., 2009). Some of the ETS proteins are known to playc.
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Figure 1. MEF in Human and Mouse
Gliomas
(A) MEF expression in the TCGA data set obtained
from humanGBM samples (n = 195) and nontumor
brain tissue (n = 10) (***p = 2.366e09, Student’s
t test).
(B) Kaplan Meier survival curves of TCGA GBM
patients: low level of MEF (calculated as less than
one standard deviation from the mean of diploid
tumors) significantly correlates with better overall
survival (***log-rank p value, p = 0.000386).
(C) Top panel: MEF mRNA level detected by RT
PCR is higher in PDGF-driven mouse GBMs (T)
compared to normal tissue (N). Data are normal-
ized to GAPDH expression. Results are presented
as mean ± SD (***p < 0.0001, Student’s t test).
Bottom panel: western blot showing that MEF
protein level is higher in PDGF-driven mouse
GBMs compared to normal tissue.
(D) Kaplan Meier survival curves of PDGF gliomas
generated in Ntv-a Mef+/+ versus Mef/ mice.
MEF loss increases overall survival and reduces
gliomagenesis (log-rank p value, *p = 0.02).
(E) Left panel: mouse gliomas lacking MEF show
significantly lower percentage of high-grade
versus low-grade tumors (Fisher’s exact test,
*p = 0.027); right panel: contingency table pre-
senting the number of high-grade (HG) tumors
versus low-grade (LG) tumors in the two different
genetic backgrounds.
See also Figure S1.
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MEF Role in Pathogenesis of Gliomasa role in brain tumors (Uht et al., 2007), though so far no pub-
lished data are available regarding the role of MEF in normal
brain or in brain tumor biology. Here we show that MEF is highly
expressed in GBMs and it contributes to gliomagenesis by
promoting stem cell traits through direct activation of Sox2
expression.
RESULTS
MEF Is Highly Expressed in Human Gliomas and Its Loss
Impairs Glioma Formation in Mice
GBM represents a heterogeneous disease and recent genomic
analyses have quantified the expression level of a wide variety
of genes (Cancer Genome Atlas Research Network, 2008). We
analyzed the data set from The Cancer Genome Atlas (TCGA)
for GBMs and found MEF expression significantly elevated in
the tumor samples (n = 195) as compared to nontumor brain
tissue (n = 10) (p < 0.0001; Student’s t test) (Figure 1A and Table
S1 available online), without evidence for amplification at the
genomic level. Because MEF has previously been shown to
block the p53 pathway, we examined the p53 status of theseCell Stem Cell 11, 836–844,tumors and found no correlation between
MEF expression levels and p53 mutation
or deletion, suggesting that MEF may
function in a p53-independent manner in
glioma (Figure S1A available online).
A search conducted in the Oncomine
website (https://www.oncomine.org//) re-
vealed that in the Sun data set (Sun et al.,2006), which includes 81 human GBMs (grade IV), 25 anaplastic
astrocytomas (grade III), and 50 oligodendrogliomas (grade II),
MEF expression is significantly higher in GBMs than in lower
grade gliomas (p < 0.0001) (Figure S1B). To confirm these data
we analyzed MEF expression by qPCR in 25 human glioma
surgical samples from Memorial Sloan-Kettering Cancer Center
(MSKCC) (six oligodendrogliomas, seven anaplastic oligoden-
drogliomas, two anaplastic astrocytomas, and ten glioblas-
tomas) and found that MEF is significantly elevated in high-grade
versus low-grade gliomas (p = 0.02, Student’s t test) (Fig-
ure S1C). However, this difference might reflect a lower ratio of
tumor cells versus nontumor cells in the low-grade samples.
Lower levels of MEF were associated with a better prognosis
in a small cohort of acute myeloid leukemia patients (Fukushima
et al., 2003). We examined the TCGA GBM patient survival
data and found that low levels of MEF significantly correlated
with better overall survival in GBMs as well (log rank test,
p = 0.0008; Figure 1B). Gene expression profiling studies have
identified four molecular subclasses of GBMs based on tran-
scriptional signatures: Classical, Mesenchymal, Proneural and
Neural. Each of these subtypes has been associated withDecember 7, 2012 ª2012 Elsevier Inc. 837
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Figure 2. Mef Promotes Proliferation of
both Primary Brain Cultures and Human
Glioma Cell Lines
(A and B) Growth curve of primary brain cultures
derived fromMef/,Mef+/+ (A) andp53//Mef/,
p53//Mef+/+ (B) newborn mice.
(C–E) Growth curve of primary brain cells derived
from p53/ newborn mice (C) and human U87MG
and T98G glioma cell lines (D and E).
Results are presented as mean ± SD from
a representative of three experiments performed
in triplicate. *p < 0.05; **p < 0.001; ***p < 0.0001
(Student’s t test). See also Figure S2.
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MEF Role in Pathogenesis of Gliomasspecific signaling alterations, such as EGFR, Ras, and PDGFR
pathway activation, respectively (Verhaak et al., 2010). When
the patients were stratified according to GBM subtypes, the
Proneural subclass showed the lowest level of MEF expression
(Figure S1D) and, within this subtype, lower levels of MEF also
correlated with better overall survival (Figure S1E). When we
looked at the IDH1 status, we found that the tumors with the
lowest MEF levels within the Proneural group were predomi-
nantly IDH1 mutant tumors, whereas IDH1 wild-type Proneural
tumors had a range of MEF levels similar to the other tumor types
(data not shown).
To determine whether MEF plays an active role in gliomagen-
esis, we used the RCAS/PDGF mouse glioma model, which
closely resembles the human Proneural GBM subtype. The
RCAS/tv-a system utilizes avian leukosis virus based vectors
(RCAS) to mediate gene transfer into somatic cells, engineered
to be transgenic for its receptor (tv-a). Specifically, we used Nes-
tin tv-a (Ntv-a) mice, where the tv-a receptor is under the control
of the Nestin promoter, a well-known marker of progenitor and
neural/glial cells. First, we evaluated MEF expression in an838 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc.Ink4a/Arf null background, in which
PDGF is able to uniformly generate high-
grade gliomas that share hallmark histo-
logical features with human GBMs (Dai
et al., 2001). Using qPCR and Western
blot analysis, we found higher levels of
MEF mRNA and protein in these tumors
as compared to the contralateral normal
brain tissues (Figure 1C).
Next, to determine if lack of MEF
impacts on PDGF-induced gliomagene-
sis, Mef/ mice were crossed with
Ntv-a mice (which carry a wild-type
Ink4a/Arf locus) to generate Ntv-a Mef+/+
and Ntv-a Mef/ mice. A survival anal-
ysis of the two cohorts revealed that
loss of MEF significantly impaired
PDGF-induced glioma formation, with
MEF null mice living an average of
129 days (n = 22) and wild-type mice
living 59 days (n = 24) (p < 0.02, log rank
test) (Figure 1D). The tumors were then
scored and graded by histological
features (see Experimental Proceduresfor details). Tumors lacking MEF showed less aggressive
features, with significantly fewer high-grade gliomas (p = 0.02,
Fisher’s exact test) (Figure 1E). Thus,MEF can affect both glioma
formation and progression.
MEF Promotes Proliferation of both Mouse Primary
Brain Cultures and Human Glioma Cell Lines
As MEF has been shown to promote the transition of cells
from G1 to S (Liu et al., 2006; Sashida et al., 2009) we evalu-
ated its effect on proliferation, using both mouse primary brain
cultures and human glioma cell lines. The primary cultures
were generated from the whole brain of newborn pups, and
to investigate potential p53-independent effects, we used cells
from Mef+/+ and Mef/ mice and also from p53// Mef+/+
and p53//Mef/ mice. Cells lacking MEF grew more slowly
than the control cells (Figures 2A and 2B), while its overex-
pression in p53/ cells (Figure S2A) increased proliferation
(Figure 2C). Similarly, the overexpression of MEF in the human
U87MG and T98G glioma cell lines (Figures S2B and S2C) re-
sulted in higher rates of cell proliferation (Figures 2D and 2E).
Cell Stem Cell
MEF Role in Pathogenesis of GliomasThese data confirm the role of MEF in promoting the growth of
both mouse primary brain cultures and human glioma cell
lines.
MEFPromotesStemCell Characteristics inMouseNSCs
and Human Glioma Cell Lines
In recent years, an increasing number of studies have investi-
gated the connection between malignancy and ‘‘stemness,’’
focusing on how stem/progenitors cells, as well as neoplastic
cells, change their properties during the process of malignant
transformation. Several transcription factors are known to
induce pluripotent stem cells from differentiated cells, as well
as to maintain multipotency of NSCs (Patel and Yang, 2010).
Because MEF contributes to glioma formation and aggressive-
ness in vivo, we explored the possible role of MEF in promoting
stem cell characteristics.
NSCs and GSCs can be grown as spheres in culture, in the
absence of serum but in the presence of basic fibroblast growth
factor (bFGF) and epidermal growth factor (EGF). Although
sphere-forming assays cannot be considered an exact readout
of in vivo stem cell activity, they are useful to measure the
in vitro potential of cells to exhibit stem-cell-like traits (Pastrana
et al., 2011); therefore, we investigated whether MEF could influ-
ence the formation of neurospheres.
Freshly isolated Mef/ and Mef+/+ cells from postnatal non-
neoplastic brains were plated at different cell densities (10, 5,
and1cells/ml) in 24-well platesandgrown inneurospheremedium
for 2weeks to allow thegeneration of neurospheres.We thenper-
formed serial passages over the course of 8 weeks, generating
secondary, tertiary, and quaternary spheres. Spheres were me-
chanically dissociated every 2 weeks, and at each passage,
sphere number was assessed. We found that at a density of
1 cell/ml, lack of MEF significantly decreased generation of
secondary, tertiary, and quaternary neurospheres (Student’s
t test, p < 0.0001, at each passage) (Figure 3A). Similar results
were obtained at higher cell concentrations (5 and 10 cells/ml)
(FigureS3A).Moreover, cells lackingMEFunderwentmorpholog-
ical changes over time, with some of them becoming attached to
the bottom of the wells and presenting short elongation
processes (Figure S3B). To understand whether the decreased
sphere forming ability seen inMef/ cells was accompanied by
increased differentiation, we grew cells fromdissociated spheres
in 5% serum medium without FGF and EGF to evaluate their
differentiation potential. Phase contrast images revealed clear
differences in themorphologyof theMef+/+andMef/ cells, sug-
gesting that differentiation is more profound in cells lacking MEF
(Figure 3B). Immunofluorescence staining showed a significant
reduction in Nestin+ cells (p = 0.0006), together with a significant
increase in bothOlig2 andGFAP+ cells (p < 000.1 and p = 0.0481,
respectively, Student’s t test) inMef/ cells (Figures 3C and 3D).
These differences were detected also by Western blot analysis
(Figure 3E). Interestingly, most of the GFAP-positiveMef/ cells
showed the stellate morphology typical of astrocytes and
a brighter signal, which was confirmed by increased GFAP
protein levels measured by Western blot (Figure 3E). We failed
to detect Tuj-1+ cells in three of the four Mef/ samples, while
an average of 14.4% Tuj-1+ cells was found in four different
Mef+/+ samples (data not shown), which suggests thatMEFmight
also contribute to differentiation toward the neuronal lineage.CellTo determine whether lack of MEF could influence the stem
cell potential under more strict conditions, we generated primary
cell cultures obtained from the whole brain of newborn pups,
forced them to grow in serum for two passages, and switched
them to neurosphere medium. To evaluate possible p53-inde-
pendent effects, primary brain cultures were isolated from
different genetic backgrounds (Mef+/+, Mef/, p53//Mef+/+,
and p53// Mef/). Four days after the switch to neurosphere
medium, cells lacking MEF failed to form spheres, while both the
Mef+/+ and the p53//Mef+/+ cells were able to do so (p = 0.0003
and p = 0.0001, respectively, Student’s t test) (Figure 3F). The
impaired neurosphere formation of the p53//Mef/ cells
could be rescued by MEF re-expression (p = 0.00145, Student’s
t test) (Figure 3G and Figure S3C).
We then investigated whether MEF overexpression could
induce reprogramming signals under the same strict conditions,
influencing the sphere-forming ability of different primary and
glioma cells. We first overexpressed MEF in primary brain
cultures obtained from p53 null pups, using retroviral vectors
(Figure S2A). After antibiotic selection, the cells were grown in
serum for two passages and then switched to neurosphere
medium. We found that cells overexpressing MEF formed
more neurospheres than the control cells (p = 0.0012 at 24 hr,
p = 0.0017 at 72 hr; Student’s t test) (Figure 3H). Similar differ-
ences upon MEF overexpression were observed in the U87MG
and T98G human glioma cell lines (p < 000.1 and p < 000.1,
respectively, Student’s t test) (Figure 3I).
Lastly, we evaluated the impact of MEF on stem-like proper-
ties using human primary GSCs, with various genetic profiles.
Tumor samples, isolated from patients suffering from GBMs
and undergoing surgery at MSKCC, were dissociated and
initially grown in neurosphere medium as a monolayer on
plastic cell culture dishes coated with 10 ng/ml laminin. Specifi-
cally, we used the following cells: GBM1 (++PDGFRA, +EGFR,
MET, CDK6, PTEN, CDKN2A), GBM3 (++EGFR, +MET,
CDK6, CDKN2A,PTEN, carrying EGFRvIII mutation), and
GBM543 (++PDGFRA, ++CDK4, +(EGFR,MET,CDK6), PTEN)
(Ozawa et al., 2010; Pulvirenti et al., 2011). Using lentiviral
vectors to express shRNAs, we silenced MEF expression (Fig-
ure S3D) and found that decreased MEF levels lead to a signifi-
cant decrease in neurosphere formation in all of these three GSC
lines (p < 0.0001 for both shRNA#1 and shRNA#2), as compared
to nontargeting shRNA control (Figure 3J). Moreover, when we
performed limiting dilution neurosphere assays, we confirmed
that MEF knockdown leads to a reduced frequency of sphere-
forming cells (p < 000.1 for both shRNAs in each GSC line,
ELDA software) (Figure 3K).
Taken together, these data suggest a role for MEF in
promoting stem-cell-like features in both primary brain cultures
and glioma cell lines.
Sox2 Gene Is a Direct Target of MEF and Rescues
Sphere-Forming Ability in MEF-Defective Cells
To investigate possible mechanisms behind the ability of MEF to
promote stem-cell traits, we measured the expression level of
several genes related to pluripotency, including Sox2, Oct4,
Nanog, Klf4, Hes1, and Hey1, in MEF-transduced p53/
primary brain cells. Among these genes, we found that Sox2
and Oct4 expression was significantly increased by MEF. WeStem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc. 839
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Figure 3. MEF Promotes Stem Cell Traits of both Primary Brain Cultures and Glioma Cell Lines
(A) Neurospheres isolated from newborn pups, withMef+/+ andMef/ genetic background, respectively: MEF loss led to impaired neurosphere formation after
serial passages.
(B) Phase contrast images showingmorphological changes betweenMef+/+ andMef/ brain cells grown in 5% serum, without bFGF and EGF, for 5 days to favor
differentiation.
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MEF Role in Pathogenesis of Gliomasobserved a 3.6-fold increase in Sox2 gene expression and a 3-
fold increase in Oct4 expression level (p = 0.02 and p = 0.013,
respectively, Student’s t test) (Figure 4A). Similarly, in U87MG
and T98G cells, MEF induced a 2.1 (p = 0.017) and 1.6 (p =
0.018) -fold increase in Sox2 levels and a 1.8 (p = 0.0025) and
1.6 (p = 0.0199) -fold increase in Oct4 levels (Figure 4B).
The Sox2 promoter is known to contain ETS binding sites
(Wiebe et al., 2000), though they have not been identified in the
Oct4 promoter; therefore, we focused on Sox2 as a possible
direct downstream target of MEF. We analyzed Sox2
expression in Mef+/+ versus Mef/ and p53//Mef+/+ versus
p53//Mef/ primary brain cells and found a significant reduc-
tion in Sox2 levels in the absence of MEF (p < 0.0001, Student’s
t test) (Figures 4C and 4D). To exclude the possibility that devel-
opmental adaptation to the lack of MEF resulted in decreased
Sox2 expression, we acutely knocked down MEF in p53 null
primary brain cultures (60%) and found a significant reduction
in Sox2 expression (p = 0.015 and p = 0.0059, respectively,
Student’s t test) (Figure 4E). Thus, both the acute loss and
chronic absence of MEF substantially decreases Sox2
expression.
To test whether MEF can activate the Sox2 promoter, we
transiently transfected a Sox2 promoter-driven luciferase
reporter plasmid (Kuwabara et al., 2004) into p53 null primary
brain cells, together with MEF or an empty vector control. As
shown in Figure 4F, MEF induced a greater than 3-fold increase
in luciferase activity from the Sox2 promoter (p < 0.0001,
Student’s t test) while having no effect on Hes1 promoter-
driven luciferase activity. We also investigated whether MEF
activates the Sox2 promoter in human glioma cell lines and
found a similar upregulation (p < 0.0001, Student’s t test)
(Figures 4G and 4H).
Having identified Sox2 as a transcriptional target of MEF, we
investigated whether Sox2 overexpression could rescue the
decrease in neurosphere formation seen in cells lacking MEF.
We overexpressed Sox2 in p53//Mef/ primary brain cultures
(Figure S4B) and grew them in neurosphere conditions. The
absence of neurospheres seen in cells lacking MEF was rescued
by Sox2 overexpression (p = 0.00018, Student’s t test), indi-
cating that Sox2 acts downstream of MEF to promote neuro-
sphere formation (Figure 4I).
To confirm that Sox2 gene regulation by MEF was direct, we
performed Chromatin Immunoprecipitation (ChIP) assays using
T98G glioma cells that were transduced with a pBabe retroviral(C and D) Immunofluorescence staining and quantification ofMef+/+ andMef/ b
is quantified as percentages of total Hoechst+ cells per image (10 fields of images
scale bars indicate 50 mm.
(E) Western blot comparing Mef/ to Mef+/+ brain cells: lack of MEF lead to dec
(F) Mef+/+, Mef/, p53//Mef+/+, and p53//Mef/ primary brain cultures gro
(G) Re-expression of MEF in p53/Mef/ cells rescues their ability to form neu
(H) Micrograph showing p53/ primary brain cells transfected with pBabe-emp
graphs on the bottom show average neurosphere number per field of view.
(I) MEF overexpressing human U87MG and T98G cell lines, cultured in neurosphe
bottom show average neurosphere number per field of view.
(J) Graph bar showing decreased neurosphere formation after MEF knockdown
(K) Graph representing limiting dilution neurosphere assays in patient-derived hu
vector and pGipz MEF shRNAs #1 and #2.
Results are presented as mean ± SD from a representative of three experimen
***p < 0.0001 (Student’s t test). See also Figure S3.
Cellvector expressing a FLAG-taggedMEF cDNA or a control vector.
Using an anti-FLAG ChIP assay, we found that in human glioma
cells, MEF protein is recruited to specific regions of the Sox2
gene (which covered 1.964, 1.672, and 1.324 kb from the
transcription starting site [TSS]; p values: 0.0009, 0.003,
0.0008, respectively). No direct binding was observed at the
farthest region (3.841 kb) (Figure 4J).
DISCUSSION
The regulation of stemness is of interest to many disciplines,
including developmental biology, regenerative medicine, degen-
erative disease, and cancer. Normal stem cells are known to
play critical roles in tissue development, differentiation, and
organogenesis (Vierbuchen et al., 2010). Several transcription
factors, such as Notch, Id1, Sox2, Oct4, and others, have been
reported to control different aspects of stemness, influencing
the delicate balance between stem cell maintenance and the
promotion of stem cell differentiation. In recent years, many
studies have shown that genes involved in normal stem cell
biology also play a relevant role in tumorigenesis (Nam and Ben-
ezra, 2009) (Venere et al., 2011).
Malignant gliomas are highly aggressive cancers composed of
a heterogeneous cell population, a fraction of which exhibits
stem-like characteristics (Vescovi et al., 2006). Whether GSCs
arise from normal NSCs or from neoplastic cells that have
acquired stem cell traits is still unclear; however, it has been
proposed that the acquisition of stem cell characteristics
through the activation of stem cell gene signatures can confer
malignant potential to gliomas (Holmberg et al., 2011).
We have shown that MEF, a member of the ETS family of tran-
scription factors, contributes to gliomagenesis and promotes
stem-like characteristics. MEF is highly expressed in both
human and mouse GBMs, and GBM patients with low levels of
MEF show a significantly better overall survival. This finding
was replicated in the RCAS/PDGF model where gliomas that
lack MEF had less aggressive histological features and better
overall survival.
Genes overexpressed in cancer can affect many different
biological processes including growth, stress response, block
of apoptosis, and stemness. Uncontrolled proliferation is a key
aspect of cancer cell behavior and we found that MEF promotes
the proliferation of bothmouse primary brain cultures and human
glioma cell lines, contributing to the pathogenesis of gliomas.rain cells grown in the above condition to favor differentiation. Positive staining
were taken from four different cell lines for each genotype,Mef/ andMef+/+);
reased Nestin and increased Olig2 and GFAP protein levels.
wn in neurosphere conditions. Scale bars indicate 100 mm.
rospheres when cultured in neurosphere conditions.
ty and pBabe-MEF retroviral vectors, cultured in neurosphere conditions. Bar
re conditions, formmore neurospheres compared to control. Bar graphs on the
in patient-derived human primary GBMs (GBM1, GBM3, and GBM543).
man primary GBMs (GBM1, GBM3, and GBM543) infected with pGipz control
ts performed in triplicate, unless otherwise specified. *p < 0.05; **p < 0.005;
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Figure 4. Sox2 Gene Is Regulated by MEF
(A and B) MEF overexpression in p53/ primary
brain cells as well as in U87MG and T98G human
glioma cell lines led to increased Sox2 expression.
Data are normalized to GAPDH expression.
(C and D) Lack of MEF decreases Sox2 expres-
sion. Data are normalized to GAPDH expression.
(E) Acute knockdown of MEF in p53/ primary
brain cells led to decreased Sox2 expression. Data
are normalized to GAPDH expression.
(F–H) Dual luciferase assays showing that MEF
activates Sox2 promoter in p53/ primary brain
cells as well as T98G and U87MG human glioma
cell lines.
(I) Sox2 overexpression in p53//Mef/ primary
brain cultures grown in neurosphere conditions
rescues their ability to form neurospheres. Scale
bar indicates 100 mm. Bar graph shows average
neurosphere number per field of view.
(J) ChIP experiments were performed on T98G
glioma cells using antibody to Flag. Plotted values
are relative enrichments (y axis) to 10% input and
measured for sites in the Sox2 promoter (x axis).
Antibody against IgG was used as a nonspecific
control.
Results are presented as mean ± SD from
a representative of three experiments performed in
triplicate. *p < 0.05; **p < 0.001; ***p < 0.0001
(Student’s t test). See also Figure S4.
Cell Stem Cell
MEF Role in Pathogenesis of GliomasAnother key feature of glioma malignancy is the activation of
neural and pluripotent stem cell gene expression signatures.
We found that mouse primary brain cells that lack MEF and
silencing of MEF in human primary glioblastoma stem-like cells
each lead to an impaired capacity to generate spheres, together
with an increased differentiation potential. Conversely, MEF
overexpression increases neurosphere formation of both mouse
primary brain cells and glioma cell lines. Collectively, our data
suggest that MEF plays a role in promoting stem-like traits,842 Cell Stem Cell 11, 836–844, December 7, 2012 ª2012 Elsevier Inc.which might reflect changes in the stem
cell signature of both neoplastic and non-
neoplastic cells.
We have further implicated MEF in
promoting stem cell traits through direct
activation of Sox2 expression. The HMG-
box transcription factor Sox2 is known to
play an important role in maintaining
stem cell self-renewal within the central
nervous system (CNS) and this activity is
present in gliomas aswell (Pevny andNic-
olis, 2010). Sox2 has been described to
act as an oncogene in different human
cancers including gliomas. While the role
of Sox2 in normal brain and glioma cells
has been well documented, the transcrip-
tion factors that activate its expression in
these contexts are less clear (Denysenko
et al., 2010; Ikushima et al., 2009). We
identified Sox2 as a direct target of MEF
in mouse primary brain cells and human
glioma cell lines, because both acuteand chronic modulation of MEF levels affected Sox2 gene
expression and promoter activation. MEF directly binds to Sox2
promoter in T98Gglioma cells. We observed that overexpression
of Sox2 in p53//Mef/ cells was sufficient to rescue the
impaired ability of these cells to form neurospheres. Thus, our
data suggest that Sox2 is downstream of MEF and may be
responsible for its ability to modulate stem-like characteristics.
Given the cellular heterogeneity and molecular complexity of
gliomas, it is unclear in which contexts the stem cell property
Cell Stem Cell
MEF Role in Pathogenesis of Gliomasof self-renewal might represent a feature associated with
increased tumorigenic potential (Barrett et al., 2012). Addition-
ally, the so called ‘‘glioma stem-like cells’’ within different tumors
may vary in terms of proliferation rates, which might impact
their aggressiveness regardless of their self-renewal properties.
To date, it is often difficult to distinguish between the con-
tributions of proliferation versus self-renewal to the process of
gliomagenesis; nonetheless, self-renewal inevitably entails
proliferative events. Adding to the intricacy, acquisition of
reprogramming signals generated by alterations in specific
genes or pathways (Notch, Id1, Sox2, Oct4, etc.) might differen-
tially impact on these two diverse aspects.
Our work defines the role of MEF in promoting stem cell
features in both primary mouse brain cells and human glioblas-
toma cells via direct regulation of Sox2 expression, providing
insights into the multifaceted regulation of stemness. Further
work is necessary to better define the MEF/Sox2-mediated
acquisition of stem cell traits and whether it modulates the
response to chemotherapy and radiotherapy.
EXPERIMENTAL PROCEDURES
TCGA Analysis
TCGAdatawas downloaded from the TCGAData Portal (https://tcga-data.nci.
nih.gov/) or the cBio Cancer Genomics Portal (Cerami et al., 2012) (http://
cbioportal.org/). Subtype information was retrieved from Verhaak et al.
(2010). Low MEF expression in the TCGA data set was defined using the
median expression data (median of three platforms, see Verhaak et al.,
2010) as one standard deviation lower than the mean of all tumors. All other
analyses were performed using data from the Affymetrix U133 microarray
platform. Expression data was available for 195 tumors and 10 normal brain
samples (Table S1).
Generation of Primary Brain Cultures and Primary Brain
Neurosphere and Neurosphere Formation Assay
The Mef+/+, Mef/, p53/, and p53/Mef/ primary brain cultures were
prepared with mechanical dissociation of the whole brain from newborn
mice. The cells were then filtered through a 70 mm Nylon strainer and plated
in 10 cm culture dishes (with the procedure derived with minor modifications
from a previously described experimental method) (Dai et al., 2001). Mouse
primary brain cultures, as well as T98G and U87MG human glioma cell lines,
were plated at 20 cells/ml in neurosphere medium. Mouse primary brain neuro-
sphereswere isolated as previously described (Bleau et al., 2009) and plated at
different concentrations (10, 5, and 1 cell/ml). Human primary glioblastoma
neurospheres were freshly isolated from patients suffering from GBMs and
undergoing surgery at MSKCC. Primary GBM samples were dissociated,
plated at different concentrations (1, 0.5, 0.2, and 0.1 cells/ml) and grown in
neurosphere medium. Neurosphere medium consisted of NSC Basal Medium,
NSC proliferation supplements, 10 ng/ml EGF, 20 ng/ml basic-FGF, and 1 mg/
ml Heparin (Stem Cell Technologies, Vancouver, Canada). Neurosphere
number was established by counting the number of neurospheres per well
or, for U87MG and T98G, by taking pictures of the central part of the plates
and then counting the neurosphere number per field of view.
SUPPLEMENTAL INFORMATION
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